These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36592291)

  • 1. Minimal symptom expression achievement over time in generalized myasthenia gravis.
    Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kuwabara S
    Acta Neurol Belg; 2023 Jun; 123(3):979-982. PubMed ID: 36592291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcomes and prognostic factors in generalized myasthenia gravis.
    Ozawa Y; Uzawa A; Yasuda M; Kojima Y; Onishi Y; Oda F; Kanai T; Himuro K; Kawaguchi N; Kuwabara S
    J Neurol; 2021 Oct; 268(10):3781-3788. PubMed ID: 33774750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nomogram for short-term outcome assessment in AChR subtype generalized myasthenia gravis.
    Zhao R; Wang Y; Huan X; Zhong H; Zhou Z; Xi J; Da Y; Lei L; Chang T; Ruan Z; Luo L; Li S; Yang H; Li Y; Luo S; Zhao C
    J Transl Med; 2021 Jun; 19(1):285. PubMed ID: 34193193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Minimal symptom expression' in patients with acetylcholine receptor antibody-positive refractory generalized myasthenia gravis treated with eculizumab.
    Vissing J; Jacob S; Fujita KP; O'Brien F; Howard JF;
    J Neurol; 2020 Jul; 267(7):1991-2001. PubMed ID: 32189108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Utility of Acetylcholine Receptor Antibody Testing in Ocular Myasthenia Gravis.
    Peeler CE; De Lott LB; Nagia L; Lemos J; Eggenberger ER; Cornblath WT
    JAMA Neurol; 2015 Oct; 72(10):1170-4. PubMed ID: 26258604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
    Kupersmith MJ; Latkany R; Homel P
    Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. One-year follow-up of disease burden and medication changes in patients with myasthenia gravis: From the MG Patient Registry.
    Lee I; Leach JM; Aban I; McPherson T; Duda PW; Cutter G
    Muscle Nerve; 2022 Oct; 66(4):411-420. PubMed ID: 35673964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adequate tacrolimus concentration for myasthenia gravis treatment.
    Kanai T; Uzawa A; Kawaguchi N; Himuro K; Oda F; Ozawa Y; Kuwabara S
    Eur J Neurol; 2017 Feb; 24(2):270-275. PubMed ID: 28102047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and treatment status of antiacetylcholine receptor antibody-positive ocular myasthenia gravis.
    Isshiki Y; Mimura O; Gomi F
    Jpn J Ophthalmol; 2020 Nov; 64(6):628-634. PubMed ID: 32936398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation between myasthenia gravis-activities of daily living (MG-ADL) and quantitative myasthenia gravis (QMG) assessments of anti-acetylcholine receptor antibody-positive refractory generalized myasthenia gravis in the phase 3 regain study.
    Vissing J; O'Brien F; Wang JJ; Howard JF
    Muscle Nerve; 2018 Aug; 58(2):E21-E22. PubMed ID: 29684239
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
    Katyal N; Narula N; Govindarajan R
    J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retrospective analysis of efgartigimod use in patients with double-seronegative generalized myasthenia gravis: a case series.
    Horiuchi K; Nakamura S; Yamada K; Inoue T; Oiwa K
    Neuromuscul Disord; 2024 Jun; 39():37-41. PubMed ID: 38772072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.
    Howard JF; Bril V; Burns TM; Mantegazza R; Bilinska M; Szczudlik A; Beydoun S; Garrido FJRR; Piehl F; Rottoli M; Van Damme P; Vu T; Evoli A; Freimer M; Mozaffar T; Ward ES; Dreier T; Ulrichts P; Verschueren K; Guglietta A; de Haard H; Leupin N; Verschuuren JJGM;
    Neurology; 2019 Jun; 92(23):e2661-e2673. PubMed ID: 31118245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
    Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
    Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial.
    Howard JF; Bril V; Vu T; Karam C; Peric S; Margania T; Murai H; Bilinska M; Shakarishvili R; Smilowski M; Guglietta A; Ulrichts P; Vangeneugden T; Utsugisawa K; Verschuuren J; Mantegazza R;
    Lancet Neurol; 2021 Jul; 20(7):526-536. PubMed ID: 34146511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous hematopoietic stem cell transplant for the treatment of refractory myasthenia gravis with anti-muscle specific kinase antibodies.
    Beland B; Hahn C; Jamani K; Chhibber S; White C; Atkins H; Storek J
    Muscle Nerve; 2023 Feb; 67(2):154-157. PubMed ID: 36527328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. United States clinical practice experience with eculizumab in myasthenia gravis: symptoms, function, and immunosuppressant therapy use.
    Habib AA; Klink AJ; Muppidi S; Parthan A; Sader SC; Balanean A; Gajra A; Nowak RJ; Howard JF;
    J Neurol; 2024 Sep; 271(9):6114-6126. PubMed ID: 39052039
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of change in acetylcholine receptor antibody levels predicts myasthenia gravis outcome.
    Kojima Y; Uzawa A; Ozawa Y; Yasuda M; Onishi Y; Akamine H; Kawaguchi N; Himuro K; Noto YI; Mizuno T; Kuwabara S
    J Neurol Neurosurg Psychiatry; 2021 Sep; 92(9):963-968. PubMed ID: 33766920
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
    Sugimoto T; Yamawaki T; Naito H; Ohno N; Giga M; Kono T; Ochi K; Kohriyama T; Nomura E; Maruyama H
    Rinsho Shinkeigaku; 2022 Dec; 62(12):915-921. PubMed ID: 36450489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors affecting outcome in ocular myasthenia gravis.
    Mazzoli M; Ariatti A; Valzania F; Kaleci S; Tondelli M; Nichelli PF; Galassi G
    Int J Neurosci; 2018 Jan; 128(1):15-24. PubMed ID: 28625092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.